Jujuboside A through YY1/CYP2E1 signaling alleviated type 2 diabetes-associated fatty liver disease by ameliorating hepatic lipid accumulation, inflammation, and oxidative stress.
Ju A, an active component of SZS, protected against liver damage in T2DM by reducing lipid accumulation and inflammation, and enhancing fatty acid metabolism through PPARα activation. Potential treatment for NAFLD.
- Zhang W et al (2024).
- Chem Biol Interact.
- PubMed:
- 39059604